Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

Pages

25 results
4:38 PM, Jan 05, 2018  |  BioCentury | Finance

Burgeoning bellwethers

Keytruda pembrolizumab Primary mediastinal B cell lymphoma (PMBCL) PDUFA date 4/3/18 Myriad Genetics Inc. (NASDAQ:MYGN) BRACAnalysis
12:00 AM, Jan 05, 2015  |  BioCentury | Finance

4Q14 Stock Wrap-up: Grow early, grow often

or more prior lines of chemotherapy. The drug was approved in conjunction with companion diagnostic BRACAnalysis
12:00 AM, Nov 10, 2014  |  BioCentury | Finance

Convert resurgence

double mastectomy after finding out she had a breast cancer 1 early onset (BRCA1) mutation. BRACAnalysis
12:00 AM, Aug 18, 2014  |  BioCentury | Finance

Highlights of weekly biotech stock moves

including $107.4M in sales of breast cancer 1 early onset (BRCA1) and BRCA2 mutation test BRACAnalysis
and $18.9M in sales of BRACAnalysis Large Rearrangement Test (BART). The company provided revenue guidance of …
12:00 AM, May 12, 2014  |  BioCentury | Finance

Zeroing in on immunity

including $119.7M in sales of breast cancer 1 early onset (BRCA1) and BRCA2 mutation test BRACAnalysis
and $21.1M in sales of BRACAnalysis Large Rearrangement Test (BART). The company repurchased $41.9M in shares …
12:00 AM, Apr 07, 2014  |  BioCentury | Finance

Highlights of weekly biotech stock moves

for genetic tests for breast cancer 1 early onset (BRCA1) and BRCA2 , including Myriad's BRACAnalysis
12:00 AM, Feb 10, 2014  |  BioCentury | Finance

Confident roll of the dice(r)

Street's $176M estimate. Sales of breast cancer 1 early onset (BRCA1) and BRCA2 mutation test BRACAnalysis
were up 28% from the previous year's quarter to $141.2M, while sales of BRACAnalysis Large Rearrangement …
12:00 AM, Jan 06, 2014  |  BioCentury | Finance

Replacing what Myri-had

cancer 1 early onset (BRCA1) and BRCA2 genes. Myriad hopes to shunt sales of its BRACAnalysis
a reimbursement consultant told BioCentury the new test will face the same headwinds. Myriad sells BRACAnalysis
guidance on Nov. 5 to $700-$715 million from $690-$710 million. At the time, Myriad said BRACAnalysis
12:00 AM, Nov 11, 2013  |  BioCentury | Finance

OrbiMed's high five

a breast cancer 1 early onset (BRCA1) mutation. The Street was expecting revenues of $167.6M. BRACAnalysis
12:00 AM, Aug 19, 2013  |  BioCentury | Finance

Jumping on the gravy train

period ended June 30 increased 31% to $174.1M from $133M. The Street was expecting $160M. BRACAnalysis

Pages